In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Effect of primary cardiovascular prevention on the prevalence of metabolic syndrome

Session Poster Session III - Friday 08:30 - 12:30

Speaker Sergio Enea Masnaghetti

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2015

  • Topic : preventive cardiology
  • Sub-topic : Risk Factors and Prevention
  • Session type : Poster Session

Authors : S Masnaghetti (Tradate,IT), AM Lucioni (Tradate,IT), M Peraro (Tradate,IT), S Freri (Tradate,IT), A Mazzola (Tradate,IT), RFE Pedretti (Tradate,IT)

Authors:
S Masnaghetti1 , AM Lucioni1 , M Peraro1 , S Freri1 , A Mazzola1 , RFE Pedretti1 , 1IRCCS Foundation Salvatore Maugeri, Department of Cardiology - Tradate - Italy ,

Citation:

Purpose
Metabolic syndrome (MS) is strongly related to cardiovascular events. We tested if the prevalence of MS was reduced in the otupatients referred to our primary cardiovascular prevention programme.

Methods
Aims of primary cardiovascular prevention programmes are to control risk factors, to improve adherence to healthy behaviour and therapy and to prescribe targeted diagnostic evaluation. Visits at baseline and control at 1 year were performed. Counselling on diet and physical activity were given. Optimization of therapy was attempted and diagnostic tests were proposed. IDF and NCEPT ATP III definitions of MS were considered. In the outpatients referred to our primary cardiovascular prevention programme (66 women and 80 males) prevalence of MS and its determinants at baseline and 1 year were compared.

Results
Diagnosis of MS was impossible in 7 women and 4 men at baseline and in 4 women and 3 men at 1 year according to IDF criteria and in 5 women and 4 men at baseline and 4 women and 3 men at 1 year according to NCEPT ATP III criteria. At 1 year a significant improvement in HDL and diastolic blood pressure control and a reduction of the prevalence of MS according to NCEPT ATP III criteria in whole population (p 0,04) and in women (p 0,03) and to IDF criteria in men (p 0,04) were achieved. Results are resumed in table 1. 

Conclusion
In patients referred to primary cardiovascular prevention programme a significant improvement of HDL cholesterol and diastolic blood pressure control was achieved. Prevalence of MS was significantly reduced in total population and in women according to NCEPT ATP III and in men according to IDF criteria.

Population

women

men

baseline

1 year

p

baseline

1 year

p

baseline

1 year

p

Waist (cm)

mean (SD)

104,94 + 21,89

105,48 + 15,55

0,78

102 + 65,76

102 + 17,52

0,87

107 + 72,12

109 + 8,49

0,61

Systolic blood pressure (mm Hg)

mean (SD)

136,99 + 16,32

137,37 + 18,48

0,85

134 + 14,14

137 + 20,39

0,48

139 + 7,07

138 + 7,07

0,66

Diastolic blood pressure (mm Hg)

mean (SD)

83,12 + 8,35

81,02 + 8,61

0,03

81 + 14,14

79 + 8,5

0,18

85 + 7,07

82 + 0

0,1

HDL cholesterol (mg/dl)

mean (SD)

47,36 + 18,81

51,47 + 17,30

0,04

52 + 6,36

55 + 18,91

0,34

44 + 19,09

49 + 48,79

0,06

Tryglicerids (mg/dl)

mean (SD)

134,22 + 83,08

124,42 + 58,46

0,28

119 + 50,91

116 + 50,46

0,74

147 + 187,38

131 + 101,82

0,3

Fasting glycaemia (mg/dl)

mean (SD)

104,34 + 43,51

106,26 + 38,29

0,69

106 + 44,55

107 + 41,92

0,9

103 + 12,02

105 + 100,41

0,65

Metabolic Syndrome(IDF)

N (%)

80 (59 %)

76 (55%)

0,24

34 (58%)

38 (61%)

0,47

46 (61%)

38 (49%)

0,04

Metabolic Syndrome (NCEPT ATP III)

N (%)

67 (49%)

56 (40%)

0,04

36 (59%)

28 (45%)

0,03

31 (41%)

28 (36%)

0,42

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are